|
DGAP-News: M1 Kliniken AG
/ Key word(s): AGM/EGM/Miscellaneous
M1 Kliniken AG successfully held its Annual General Meeting 2021
After the Corona-related restrictions of the previous year, the Management Board is confident about the development of the company in the current financial year and the future. In his presentation, the Management Board gave an outline of the company's successful development in the 2020 financial year, even though considerable restrictions on business activity had to be absorbed due to the official lockdown orders. Due to the very fast achievement of high occupancy rates after the reopening of the specialist centres, the Management Board is convinced that the Corona pandemic will not have a negative impact on the further business development of M1 in the medium and long term. The first interim goal is to operate a total of approximately 50 specialist centres by the end of 2021. The Management Board also commented on the background of the 75% participation in Haemato AG at the turn of the financial years 2020/21. In addition to focusing the business activities of both companies, the private label business in the field of aesthetic medicine will be expanded. A total of 77.5% of the share capital was represented at the Annual General Meeting. On the agenda were the resolution on the appropriation of the balance sheet profit for 2020, the discharge of the members of the Management Board and Supervisory Board, and the election of the auditor for the 2021 financial year. The resolution on all items on the agenda were passed with broad majorities. The detailed voting results were published at: https://www.m1-kliniken.de/aktie/hauptversammlung.html. About M1 Kliniken AG M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group of companies offers products and services with the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at more than 40 specialist centres. The M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating theatres and 35 beds, is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been pushing ahead with internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England, Croatia and Australia. With its shareholding in HAEMATO AG, which has existed since mid-2020, M1 Kliniken AG is also in a position to exploit sales and earnings potential of treatment products in the medical-aesthetic field. Contact: M1 Kliniken AG Dr. Walter von Horstig, Management Board Grünauer Straße 5 12557 Berlin T: +49 (0)30 347 47 44 14 M: ir@m1-kliniken.de
16.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | M1 Kliniken AG |
| Grünauer Straße 5 | |
| 12557 Berlin | |
| Germany | |
| Phone: | +49 (0)30 347 47 44 14 |
| Fax: | +49 (0)30 347 47 44 17 |
| E-mail: | ir@m1-kliniken.de |
| Internet: | https://www.m1-kliniken.de |
| ISIN: | DE000A0STSQ8 |
| WKN: | A0STSQ |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1219559 |
| End of News | DGAP News Service |
|
|
1219559 16.07.2021
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
